HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 177 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $24,382,639 | +94.8% | 465,673 | +51.3% | 0.01% | +75.0% |
| Q1 2024 | $12,517,400 | +358.9% | 307,704 | +317.0% | 0.00% | +300.0% |
| Q4 2023 | $2,727,463 | -3.2% | 73,795 | +0.1% | 0.00% | 0.0% |
| Q3 2023 | $2,816,714 | +1.3% | 73,736 | -4.4% | 0.00% | 0.0% |
| Q2 2023 | $2,780,888 | -86.4% | 77,097 | -85.6% | 0.00% | -90.0% |
| Q1 2023 | $20,471,329 | -66.2% | 536,039 | -49.6% | 0.01% | -67.7% |
| Q4 2022 | $60,567,944 | +43.7% | 1,064,463 | -0.2% | 0.03% | +34.8% |
| Q3 2022 | $42,155,000 | +39.2% | 1,066,132 | +54.9% | 0.02% | +53.3% |
| Q2 2022 | $30,282,000 | +1719.8% | 688,216 | +1548.8% | 0.02% | +1400.0% |
| Q1 2022 | $1,664,000 | -5.8% | 41,741 | -5.0% | 0.00% | 0.0% |
| Q4 2021 | $1,766,000 | +6.8% | 43,932 | +8.1% | 0.00% | 0.0% |
| Q3 2021 | $1,653,000 | +410.2% | 40,645 | +469.7% | 0.00% | – |
| Q2 2021 | $324,000 | +17.0% | 7,135 | +7.5% | 0.00% | – |
| Q1 2021 | $277,000 | +5.3% | 6,640 | +7.7% | 0.00% | – |
| Q4 2020 | $263,000 | -97.4% | 6,168 | -99.4% | 0.00% | -100.0% |
| Q4 2016 | $10,214,000 | -62.1% | 1,033,808 | -53.6% | 0.01% | -64.3% |
| Q3 2016 | $26,927,000 | +40.7% | 2,229,069 | +0.5% | 0.01% | +40.0% |
| Q2 2016 | $19,132,000 | -9.0% | 2,216,929 | -0.1% | 0.01% | -9.1% |
| Q1 2016 | $21,022,000 | -33.2% | 2,219,933 | +22.2% | 0.01% | -31.2% |
| Q4 2015 | $31,476,000 | +29.7% | 1,816,288 | +0.5% | 0.02% | +33.3% |
| Q3 2015 | $24,265,000 | -48.1% | 1,806,737 | -12.7% | 0.01% | -42.9% |
| Q2 2015 | $46,728,000 | +65.9% | 2,069,425 | +4.9% | 0.02% | +61.5% |
| Q1 2015 | $28,164,000 | -33.2% | 1,972,246 | -40.6% | 0.01% | -35.0% |
| Q1 2014 | $42,147,000 | +2.6% | 3,318,700 | +21.1% | 0.02% | 0.0% |
| Q4 2013 | $41,067,000 | +33.1% | 2,739,600 | -2.0% | 0.02% | +25.0% |
| Q3 2013 | $30,863,000 | +88.6% | 2,795,600 | +35.7% | 0.02% | +77.8% |
| Q2 2013 | $16,363,000 | – | 2,060,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
| BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
| DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
| SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
| First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
| Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
| Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
| Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |